Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引：95

作者：

Fizazi, K. ^{[1
]}

Greco, F. A. ^{[2
]}

Pavlidis, N. ^{[3
]}

Pentheroudakis, G. ^{[3
]}

机构：

[1] Univ Paris, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[2] Centennial Med Ctr, Nashville, TN USA

[3] Univ Ioannina, Dept Med Oncol, GR-45110 Ioannina, Greece

[4] ESMO Head Off, CH-6962 Viganello Lugano, Switzerland

来源：

ANNALS OF ONCOLOGY | 2011年 / 22卷

关键词：

CARCINOMA; MANAGEMENT; TUMORS;

D O I：

10.1093/annonc/mdr389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：vi64 / vi68

页数：5

共 26 条

[1] ANALYSIS OF A DIAGNOSTIC STRATEGY FOR PATIENTS WITH SUSPECTED TUMORS OF UNKNOWN ORIGIN [J].

ABBRUZZESE, JL ;

ABBRUZZESE, MC ;

LENZI, R ;

HESS, KR ;

RABER, MN .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2094-2103

[2]

BRIASOULIS E, 1997, ONCOLOGIST, V2, P142

[3] Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) [J].

Bugat, R ;

Bataillard, A ;

Lesimple, T ;

Voigt, JJ ;

Culine, S ;

Lortholary, A ;

Merrouche, Y ;

Ganem, G ;

Kaminsky, MC ;

Negrier, S ;

Perol, M ;

Laforêt, C ;

Bedossa, P ;

Bertrand, G ;

Coindre, JM ;

Fizazi, K .

BRITISH JOURNAL OF CANCER, 2003, 89 (Suppl 1) :S59-S66

[4] Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) [J].

Culine, S ;

Lortholary, A ;

Voigt, JJ ;

Bugat, R ;

Théodore, C ;

Priou, F ;

Kaminsky, MC ;

Lesimple, T ;

Pivot, X ;

Coudert, B ;

Douillar, JY ;

Merrouche, Y ;

Allouache, J ;

Goupil, A ;

Négrier, S ;

Viala, J ;

Petrow, P ;

Bouzy, J ;

Laplanche, A ;

Fizazi, K .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3479-3482

[5] Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site [J].

Culine, S ;

Kramar, A ;

Saghatchian, M ;

Bugat, R ;

Lesimple, T ;

Lortholary, A ;

Merrouche, Y ;

Laplanche, A ;

Fizazi, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4679-4683

[6] Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis [J].

Golfinopoulos, Vassilis ;

Pentheroudakis, George ;

Salanti, Georgia ;

Nearchou, Andreas D. ;

Ioannidis, John P. A. ;

Pavlidis, Nicholas .

CANCER TREATMENT REVIEWS, 2009, 35 (07) :570-573

[7] Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction [J].

Greco, F. Anthony ;

Spigel, David R. ;

Yardley, Denise A. ;

Erlander, Mark G. ;

Ma, Xiao-Jun ;

Hainsworth, John D. .

ONCOLOGIST, 2010, 15 (05) :500-506

[8]

Greco FA, 2009, MOL DIAGN THER, V13, P367, DOI 10.2165/11530360-000000000-00000

[9] Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site A Randomized, Phase III Sarah Cannon Oncology Research Consortium Trial [J].

Hainsworth, John D. ;

Spigel, David R. ;

Clark, Bobby L. ;

Shipley, Dianna ;

Thompson, Dana S. ;

Farley, Cynthia ;

West-Osterfield, Kimberly ;

Lane, Cassie M. ;

Cescon, Terrence ;

Bury, Martin J. ;

Greco, F. Anthony .

CANCER JOURNAL, 2010, 16 (01) :70-75

[10] Parallel progression of primary tumours and metastases [J].

Klein, Christoph A. .

NATURE REVIEWS CANCER, 2009, 9 (04) :302-312

← 1 2 3 →